ヘアリー細胞白血病治療の市場規模、シェア、動向分析レポート：治療別、最終用途別、地域別、セグメント別予測、2024年～2030年

ヘアリー細胞白血病治療市場の成長と動向：

Grand View Research, Inc.の調査レポートによると、世界のヘアリー細胞白血病治療市場規模は2030年までに1億4,770万米ドルに達し、予測期間中にCAGR 5.4％で成長すると予測されています。

この成長の原動力は、特に高齢化社会におけるヘアリー細胞白血病（HCL）の罹患率の上昇であり、これにより効果的な治療に対する需要が高まっています。標的治療薬やモノクローナル抗体などの新規治療薬のイントロダクションは、治療の選択肢を大幅に拡大し、患者の予後を改善し、市場の成長をさらに後押ししています。特に先進地域における認知度の向上と高度な医療インフラの整備も、患者が最新の治療選択肢にアクセスできるようにするため、HCL治療の採用を促進する上で重要な役割を果たしています。

臨床試験では、BRAF阻害剤とMEK阻害剤などの併用療法が治療効果を大幅に高めることが示されており、HCL患者に新たな希望をもたらしています。さらに、現在進行中の個別化医療の研究は、個々の患者のプロファイルに合わせて治療を調整することを目的としており、副作用を最小限に抑えながら治療成績を改善できる可能性があります。このアプローチは、各患者固有のニーズに対応し、より効果的で安全な治療法につながるため、特に有望です。

2023年9月に米国国立医学図書館から発表された研究は、古典的HCLの臨床的特徴についてさらなる洞察を与えています。この研究では、脾腫が全患者の最も一般的な臨床的特徴（100％）であったと報告しています。その他の重要な所見としては、75％の患者で肝腫大、58.33％の患者で汎血球減少がみられ、残りの患者は二血球減少を示しました。患者の66.6％の末梢血塗抹標本（PBS）では有毛細胞が観察され、骨髄吸引（BMA）では25％の症例でドライタップが観察されました。骨髄穿刺生検所見では、92％の患者で高細胞性であり、ごく一部（8％）で低細胞性を示しました。これらの所見は、HCLの複雑性を強調するものであり、特にこの疾患の多様な症状と診断および管理における課題を考慮すると、治療アプローチにおける継続的な研究と革新の必要性を強調するものです。

ヘアリー細胞白血病治療市場レポートハイライト

• 標的治療セグメントは2023年に32.45%の最大シェアを占め、予測期間中に7.5%のCAGRで最速の成長が見込まれます。
• 病院セグメントは2023年に64.34%の最大シェアを占めました。病院は、HCLの効果的な治療に不可欠な腫瘍専門医療を含む包括的なサービスを提供しているからです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ヘアリー細胞白血病治療市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場見通し
• 市場力学
  • 市場 促進要因分析
  • 市場抑制要因分析
• ヘアリー細胞白血病治療市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • パイプライン分析

第4章 ヘアリー細胞白血病治療市場：治療別推定・動向分析

• ヘアリー細胞白血病治療市場：治療ダッシュボード
• ヘアリー細胞白血病治療市場：治療変動分析
• ヘアリー細胞白血病治療市場：治療収益
• 化学療法
• 標的療法
• 免疫療法
• その他

第5章 ヘアリー細胞白血病治療市場：最終用途別推定・動向分析

• ヘアリー細胞白血病治療市場：最終用途ダッシュボード
• ヘアリー細胞白血病治療市場：最終用途変動分析
• ヘアリー細胞白血病治療市場：最終用途収益
• 病院
• 専門クリニック
• その他

第6章 ヘアリー細胞白血病治療市場：地域別推定・動向分析、治療別、最終用途別

• 地域ダッシュボード
• 市場規模と予測動向分析、2018年から2030年
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第7章 競合情勢

• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023年
• 企業プロファイル
  • Pfizer Inc
  • F. Hoffmann La Roche AG
  • Janssen Global Services
  • Emcure Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Amgen, Inc.
  • Hospira
  • AbbVie
  • AstraZeneca

List of Tables

• Table 1 List Of Abbreviation
• Table 2 North America Hairy Cell Leukemia Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 3 North America Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 4 North America Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 5 U.S. Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 6 U.S. Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 7 Canada Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 8 Canada Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 9 Europe Hairy Cell Leukemia Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 10 Europe Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 11 Europe Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 12 Germany Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 13 Germany Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 14 UK Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 15 UK Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 16 France Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 17 France Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 18 Italy Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 19 Italy Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 20 Spain Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 21 Spain Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 22 Denmark Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 23 Denmark Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 24 Sweden Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 25 Sweden Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 26 Norway Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 27 Norway Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 28 Asia Pacific Hairy Cell Leukemia Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 29 Asia Pacific Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 31 China Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 32 China Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 33 Japan Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 34 Japan Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 35 India Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 36 India Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 37 South Korea Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 38 South Korea Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 39 South Korea Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 40 Australia Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 41 Australia Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 42 Thailand Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 43 Thailand Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 44 Latin America Hairy Cell Leukemia Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 45 Latin America Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 46 Latin America Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 47 Brazil Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 48 Brazil Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 49 Mexico Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 50 Mexico Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 51 Argentina Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 52 Argentina Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 53 MEA Hairy Cell Leukemia Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 54 MEA Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 55 MEA Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 56 South Africa Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 57 South Africa Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 58 Saudi Arabia Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 59 Saudi Arabia Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 60 UAE Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 61 UAE Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 62 Kuwait Hairy Cell Leukemia Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 63 Kuwait Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 64 Kuwait Hairy Cell Leukemia Treatment Market, By End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Hairy Cell Leukemia Treatment Market: Market Outlook
• Fig. 14 Hairy Cell Leukemia Treatment Competitive Insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Hairy Cell Leukemia Treatment Market Driver Impact
• Fig. 18 Hairy Cell Leukemia Treatment Market Restraint Impact
• Fig. 19 Hairy Cell Leukemia Treatment Market Strategic Initiatives Analysis
• Fig. 20 Hairy Cell Leukemia Treatment Market: Treatment Movement Analysis
• Fig. 21 Hairy Cell Leukemia Treatment Market: Treatment Outlook And Key Takeaways
• Fig. 22 Chemotherapy market estimates and forecast, 2018 - 2030
• Fig. 23 Targeted therapy market estimates and forecast, 2018 - 2030
• Fig. 24 Immunotherapy market estimates and forecast, 2018 - 2030
• Fig. 25 Other market estimates and forecast, 2018 - 2030
• Fig. 26 Hairy Cell Leukemia Treatment Market: End Use Movement Analysis
• Fig. 27 Hairy Cell Leukemia Treatment Market: End Use Outlook And Key Takeaways
• Fig. 28 Hospitals market estimates and forecast, 2018 - 2030
• Fig. 29 Specialty clinics market estimates and forecast, 2018 - 2030
• Fig. 30 Global Hairy Cell Leukemia Treatment Market: Regional Movement Analysis
• Fig. 31 Global Hairy Cell Leukemia Treatment Market: Regional Outlook And Key Takeaways
• Fig. 32 Global Hairy Cell Leukemia Treatment market share and leading players
• Fig. 33 North America, by country
• Fig. 34 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 U.S. key country dynamics
• Fig. 36 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Canada key country dynamics
• Fig. 38 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Mexico key country dynamics
• Fig. 40 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 UK key country dynamics
• Fig. 43 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Germany key country dynamics
• Fig. 45 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 France key country dynamics
• Fig. 47 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Italy key country dynamics
• Fig. 49 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Spain key country dynamics
• Fig. 51 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Denmark key country dynamics
• Fig. 53 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Sweden key country dynamics
• Fig. 55 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Norway key country dynamics
• Fig. 57 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 China key country dynamics
• Fig. 60 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Japan key country dynamics
• Fig. 62 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 India key country dynamics
• Fig. 64 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Thailand key country dynamics
• Fig. 66 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 South Korea key country dynamics
• Fig. 68 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Australia key country dynamics
• Fig. 70 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Brazil key country dynamics
• Fig. 73 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Argentina key country dynamics
• Fig. 75 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 South Africa key country dynamics
• Fig. 78 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Saudi Arabia key country dynamics
• Fig. 80 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 UAE key country dynamics
• Fig. 82 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Kuwait key country dynamics
• Fig. 84 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Hair Cell Leukemia Treatment Market Growth & Trends:

The global hairy cell leukemia treatment market size is estimated to reach USD 147.7 million by 2030, growing at a CAGR of 5.4% during the forecast period, according to a report by Grand View Research, Inc. This growth is driven by the rising incidence of hairy cell leukemia (HCL), particularly among aging populations, which increases the demand for effective treatments. The introduction of novel therapeutics, such as targeted therapies and monoclonal antibodies, has significantly expanded treatment options, improving patient outcomes and further fueling market growth. Enhanced awareness and the availability of advanced healthcare infrastructure, especially in developed regions, also play a crucial role in driving the adoption of HCL treatments, ensuring that patients can access the latest therapeutic options.

Clinical trials have shown that combination therapies, such as BRAF and MEK inhibitors, can significantly enhance treatment efficacy, offering new hope for patients with HCL. Moreover, ongoing research into personalized medicine aims to tailor treatments to individual patient profiles, potentially improving outcomes while minimizing side effects. This approach is particularly promising as it addresses each patient's unique needs, leading to more effective and safer therapies.

A study published by the National Library of Medicine in September 2023 provides further insights into the clinical features of classical HCL. The study reported that splenomegaly was all patients' most common clinical feature (100%). Other significant findings included hepatomegaly in 75% of patients and pancytopenia in 58.33%, with the remaining patients exhibiting bicytopenia. Hairy cells were observed in the peripheral blood smear (PBS) of 66.6% of patients, while bone marrow aspirates (BMA) resulted in a dry tap in 25% of cases. Bone marrow trephine biopsy findings indicated hypercellularity in 92% of patients, with a small percentage (8%) showing hypocellularity. These findings underscore the complexity of HCL and the necessity for continued research and innovation in treatment approaches, particularly in light of the disease's varied presentations and challenges in diagnosis and management.

Hairy Cell Leukemia Treatment Market Report Highlights:

• The targeted therapy segment held the largest share of 32.45% in 2023 and is also expected to grow at the fastest CAGR of 7.5% during the forecast period
• The hospitals segment held the largest share of 64.34% in 2023 as they provide a comprehensive range of services, including specialized oncology care, which is crucial for the effective treatment of HCL
• Some of the prominent players in market are Pfizer Inc; F. Hoffmann La Roche AG; Janssen Global Services; Emcure Pharmaceuticals; Dr. Reddy's Laboratories; Amgen, Inc.; Hospira; AbbVie; AstraZeneca

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecast timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database.
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Hairy Cell Leukemia Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Prevalence Of Hairy Cell Leukemia
    • 3.2.1.2. Advancements In Targeted Therapies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Treatment Costs
    • 3.2.2.2. Lack of Awareness and Diagnostic Challenges
• 3.3. Hairy Cell Leukemia Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Hairy Cell Leukemia Treatment Market: Treatment Estimates & Trend Analysis

• 4.1. Hairy Cell Leukemia Treatment Market: Treatment Dashboard
• 4.2. Hairy Cell Leukemia Treatment Market: Treatment Movement Analysis
• 4.3. Hairy Cell Leukemia Treatment Market by Treatment, Revenue (USD Million)
• 4.4. Chemotherapy
  • 4.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.5. Targeted Therapy
  • 4.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.6. Immunotherapy
  • 4.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.7. Other
  • 4.7.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 5. Hairy Cell Leukemia Treatment Market: End Use Estimates & Trend Analysis

• 5.1. Hairy Cell Leukemia Treatment Market: End Use Dashboard
• 5.2. Hairy Cell Leukemia Treatment Market: End Use Movement Analysis
• 5.3. Hairy Cell Leukemia Treatment Market by End Use, Revenue (USD Million)
• 5.4. Hospitals
  • 5.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.5. Specialty Clinics
  • 5.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 6. Hairy Cell Leukemia Treatment Market: Regional Estimates & Trend Analysis, By Treatment, and By End Use

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.6. Singapore
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Singapore market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. List of key distributors and channel partners
  • 7.2.2. Key customers
  • 7.2.3. Key company market share analysis, 2023
• 7.3. Company Profiles
  • 7.3.1. Pfizer Inc
    • 7.3.1.1. Company overview
    • 7.3.1.2. Financial performance
    • 7.3.1.3. Product benchmarking
    • 7.3.1.4. Strategic initiatives
  • 7.3.2. F. Hoffmann La Roche AG
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Janssen Global Services
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Emcure Pharmaceuticals
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Dr. Reddy's Laboratories
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Amgen, Inc.
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Hospira
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. AbbVie
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. AstraZeneca
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives